Abstract
Despite numerous studies, the best postremission therapy in acute myeloid leukemia (AML) is a subject of intense controversy. Major prognostic factors for disease outcome are the genetic alterations of AML, patient's age, and performance status. AML is more common in older adults, with a median age of 72 years. However, in this age group the unfavorable cytogenetics dominates at a time when biologically it may be most difficult to administer optimal intensive therapy. Autologous stem cell transplantation (ASCT) enables the administration of high-dose therapy supported by stem cell infusion with a treatment-related toxicity not significantly higher than that associated with chemotherapy and significantly lower than in allogeneic stem cell transplantation. The dilemma of best postremission therapy has not been resolved because of the paucity of randomized controlled studies, especially in various cytogenetic risk and age groups. Instead, the use of genetic randomization by donor availability, analysis of outcome based on intention-to-treat, and mixed populations in the registry data produce variable results. ASCT has been associated with prolonged disease-free survival as compared to chemotherapy, especially in the favorable and ...Continue Reading
References
Dec 21, 2004·British Journal of Haematology·Dimitri A BreemsBob Löwenberg
Nov 28, 2006·Leukemia·A-L HerrUNKNOWN Acute Leukemia Working Party or the European Group for Blood and Marrow Transplantation
Jul 9, 2008·Blood·Jacob M Rowe
Mar 19, 2011·Blood·Hugo F FernandezMartin S Tallman
Sep 29, 2011·Blood·Edo VellengaUNKNOWN Swiss Group for Clinical Cancer Research Collaborative Group (SAKK)
Dec 27, 2011·The Lancet Oncology·Markus PfirrmannUNKNOWN Study Alliance Leukaemia (SAL)
May 1, 2012·Bone Marrow Transplantation·J R PasswegUNKNOWN European Group for Blood and Marrow Transplantation (EBMT)
Jun 19, 2012·Bone Marrow Transplantation·J PidalaC Anasetti
Aug 23, 2012·American Journal of Hematology·Romain GuièzeUNKNOWN GOELAMS
Sep 6, 2012·Nature Reviews. Clinical Oncology·Jan J CornelissenGert J Ossenkoppele
Sep 19, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Krzysztof MrózekClara D Bloomfield
Dec 18, 2012·Blood·Stephen J Forman, Jacob M Rowe
Feb 27, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Alan K BurnettNigel Russell
May 2, 2013·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·James M ForanDaniel J Weisdorf
Jul 19, 2013·Blood·Richard F SchlenkBob Löwenberg
Jul 31, 2014·British Journal of Haematology·Ama Z S RohatinerAndrew Lister
Sep 23, 2014·European Journal of Haematology·Patrice ChevallierMohamad Mohty
Nov 22, 2014·Acta Haematologica·Ki-Seong EomChong-Won Park
Nov 25, 2014·Haematologica·Richard F Schlenk
Nov 28, 2014·Leukemia·J J CornelissenB Löwenberg
Dec 31, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Christoph RölligGerhard Ehninger
Feb 1, 2015·Haematologica·Norbert-Claude GorinUNKNOWN Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
Jun 27, 2015·Seminars in Hematology·Felix S LichteneggerMarion Subklewe
Citations
Feb 15, 2017·Bone Marrow Transplantation·V BlumT Pabst
Dec 16, 2017·International Journal of Hematology·Toshihiro MiyamotoUNKNOWN Japan Study Group for Cell Therapy and Transplantation (JSCT)
Dec 1, 2017·Blood Cancer Journal·Sarah BertoliChristian Récher
Apr 4, 2019·Leukemia & Lymphoma·Ofrat Beyar-KatzTsila Zuckerman
Jul 1, 2017·Pathology Oncology Research : POR·Grzegorz HelbigSławomira Kyrcz-Krzemień
Dec 1, 2016·International Journal of Hematologic Oncology·Germana CastelliUgo Testa
Feb 28, 2019·Acta Haematologica·Zhichao LiSiguo Hao
May 13, 2021·Transfusion Medicine and Hemotherapy : Offizielles Organ Der Deutschen Gesellschaft Fur̈ Transfusionsmedizin Und Immunham̈atologie·Katharina KriegsmannPatrick Wuchter